Construction and expression of human PTEN tumor suppressor gene recombinant adenovirus vector

Abstract

The recombinant defective adenovirus vector carrying human PTEN tumor suppressor gene was constructed by using AdEasy-1 system and its expression was detected in human breast cancer cell line MDA-MB-468. Human PTEN cDNA was cloned into adenovirus shuttle plasmid pAdTrack-CMV to generate a recombinant plasmid pAdTrack-CMV-PTEN, then homologeous recombination was carried out in the E. coli BJ5183 by contransforming linearized shuttle vector with adenovirus backbone plasmid pAdEasy-1. The newly recombined defective adenovirus vector Ad-PTEN containing green fluorescent protein (GFP) was packaged and propagated in 293 cells. After being purified by cesium chloride gradient centrifugation, the adenovirus was transfected into human breast cancer cell line MDA-MB-468 in vitro. The expression of PTEN mRNA and protein in infected human breast cancer cell line MDA-MB-468 was detected by RT-PCR and Western blot respectively. The recombinant defective adenovirus vector carrying PTEN gene was constructed successfully. The viral titer of purified adenovirus was 2.5×10¹⁰ pfu/mL, and about 70% breast cancer cells were infected with Ad-PTEN when multiplicity of infection (MOI) reached 50. The exogenous PTEN mRNA and protein were expressed in MDA-MB-468 cells infected with Ad-PTEN by RT-PCR and Western blot. The recombinant defective adenovirus vector of PTEN gene was constructed successfully using AdEasy-1 system rapidly, which paved a sound foundation for gene study of breast cancer.

Keywords

adenovirus vector / PTEN / breast carcinoma / homologeous recombination

References

[1] LiJ, YenC, LiawD, et al.. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275: 1943-1947

[2] TengD H F, HuR, LinH, et al.. MMAC₁/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 1997, 57: 5221-5225

[3] ChenQ Y, ChenD D. Advances in multifunction PTEN gene and breast cancer. Guo Wai Yi Xue Wai Ke Xue Fen Ce (Chinese), 2002, 29: 360-362

[4] PanigrahiA R, PinderS E, ChanS Y, et al.. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol, 2004, 204: 93-100

[5] DepowskiP L, RosenthalS I, RossJ S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol, 2001, 14: 672-676

[6] LeeJ S, KimH S, KimY B, et al.. Reduced PTEN expression is associated with poor outcome and angiogenesis in invasive ductal carcinoma of the breast. Appl Immuno-histochem Mol Morphol, 2004, 12: 205-210

[7] RobbinsP D, GhivizzaniS C. Viral vectors for gene therapy. Pharmacol Ther, 1998, 80: 35-47

[8] HeT C, ZhouS, Da CostoL T, et al.. A simplified system for generating recombinant adenovirus. Proc Natl Acad Sci USA, 1998, 95: 2509-2514